Ospemifene vs. Conjugated Estrogens in the Treatment of Postmenopausal Sexual Dysfunction
Status:
Terminated
Trial end date:
2017-09-29
Target enrollment:
Participant gender:
Summary
Vulvovaginal atrophy (VVA) is a condition that impacts up to 60% of the growing
postmenopausal female population, and the most common symptom is dyspareunia. Vaginal
estrogen is the most common treatment for VVA, but it only marginally improves overall sexual
function, and many women and clinicians avoid using it because of the risks of exogenous
estrogen use during menopause. Ospemifene is a non-estrogen selective estrogen receptor
modulator (SERM) that is FDA-approved for treating dyspareunia related to VVA, and has shown
superb improvements in overall sexual health. 104 women will be randomized to receive 12
weeks of 60mg oral ospemifene, taken daily, or 12 weeks of 0.5mg vaginal conjugated
estrogens, which is placed vaginally twice per week. The improvements in sexual health and
VVA symptom severity will be compared in each group. This study will help determine if
ospemifene is a better treatment medication than conjugated estrogens.